107 related articles for article (PubMed ID: 6686449)
1. Comparison of in vitro behaviour and in vivo efficacy of two 7S-immunoglobulin preparations for intravenous use.
Stephan W; Dichtelmüller H
Arzneimittelforschung; 1983; 33(11):1538-40. PubMed ID: 6686449
[TBL] [Abstract][Full Text] [Related]
2. [Properties and efficacy of a human immunoglobulin M preparation for intravenous administration].
Stephan W; Dichtelmüller H; Schedel I
Arzneimittelforschung; 1985; 35(6):933-6. PubMed ID: 4026919
[TBL] [Abstract][Full Text] [Related]
3. Purity, anticomplementary activity, and viral antibody profile of NIG preparations for intravenous and intramuscular use.
Scheiermann N; Kuwert EK
Dev Biol Stand; 1979; 44():165-71. PubMed ID: 544291
[TBL] [Abstract][Full Text] [Related]
4. [Chemical modification with beta-propiolactone as a general concept for the production of intravenously tolerable immunoglobulin preparations].
Stephan W
Beitr Infusionther Klin Ernahr; 1983; 11():20-5. PubMed ID: 6686024
[No Abstract] [Full Text] [Related]
5. Efficacy of intravenous immunoglobulin preparations against viral and bacterial infections in mouse protection tests.
Stephan W; Dichtelmüller H
Infection; 1983; 11(4):227-31. PubMed ID: 6618678
[TBL] [Abstract][Full Text] [Related]
6. [The effect of immunoglobulin M-enriched intravenous immunoglobulins against bacterial infections and on the neutralization of bacterial toxins].
Dichtelmüller H; Stephan W
Arzneimittelforschung; 1987 Nov; 37(11):1273-6. PubMed ID: 3440036
[TBL] [Abstract][Full Text] [Related]
7. [Prophylaxis and therapy with gamma globulin. General characterization and clinical use of gamma globulin preparations].
Barandun S; Skvaril F; Morell A
Schweiz Med Wochenschr; 1976 Apr; 106(16):533-42. PubMed ID: 62393
[TBL] [Abstract][Full Text] [Related]
8. Differences among available immunoglobulin preparations for intravenous use.
Skvaril F; Gardi A
Pediatr Infect Dis J; 1988 May; 7(5 Suppl):S43-8. PubMed ID: 2456510
[TBL] [Abstract][Full Text] [Related]
9. [Comparative protein analytic studies of various intravenous 7S-immunoglobulin preparations].
Fateh-Moghadam A; Wick M; Simon H
Immun Infekt; 1984 Feb; 12(1):45-50. PubMed ID: 6532946
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of various immunoglobulin preparations administered by the intravenous route in peritonitis in the rat model].
Hart H; Seifert J; Brendel W
Arzneimittelforschung; 1987 Feb; 37(2):170-4. PubMed ID: 3580020
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
12. [Beta-propiolactone as a sterilizing agent in the manufacture of intravenous immunoglobulin preparations].
Stephan W; Dichtelmüller H
Arzneimittelforschung; 1983; 33(9):1230-1. PubMed ID: 6416260
[TBL] [Abstract][Full Text] [Related]
13. Undegraded human immunoglobulin for intravenous use.
Stephan W
Vox Sang; 1975; 28(6):422-37. PubMed ID: 807036
[TBL] [Abstract][Full Text] [Related]
14. The dual phases of the response to neonatal exposure to a VH family-restricted staphylococcal B cell superantigen.
Silverman GJ; Nayak JV; Warnatz K; Hajjar FF; Cary S; Tighe H; Curtiss VE
J Immunol; 1998 Nov; 161(10):5720-32. PubMed ID: 9820554
[TBL] [Abstract][Full Text] [Related]
15. [Use of native and lyophilized suspensions of protein A-producing staphylococci for immunoglobulin adsorption and the determination of the antibody class in human blood serum].
Vinogradov EIa; Khazenson LB; Smorodinova IP; Nikolaeva TA; Safonova NV
Lab Delo; 1980; (2):71-4. PubMed ID: 6153423
[No Abstract] [Full Text] [Related]
16. The humoral immune response in rabbits infected with Treponema pallidum: Comparison of antibody levels measured by the staphylococcal protein A-IgG (SPA-TP) microassay with VDRL, FTA-Abs, and TPI antibody responses during the development of acquired resistance to challenge.
Pepose JS; Bishop NH; Feigenbaum S; Miller JN; Zeltzer PM
Sex Transm Dis; 1980; 7(3):125-9. PubMed ID: 7003774
[TBL] [Abstract][Full Text] [Related]
17. Placental transfer of class G immunoglobulins treated with beta-propiolactone (beta-PL) for intravenous application--a case report.
Höckel M; Kaufmann R
J Perinat Med; 1986; 14(3):205-8. PubMed ID: 3783391
[TBL] [Abstract][Full Text] [Related]
18. [Comparative protein chemistry studies on Factor VIII concentrates].
Kienast K; Trobisch H
Arzneimittelforschung; 1984; 34(8):895-900. PubMed ID: 6437415
[TBL] [Abstract][Full Text] [Related]
19. Comparison of several in vitro assay methods for the quantitative determination of complement consumption ('binding') by gammaglobulin preparations.
Seiler FR; Peukert A; Kanzy EJ
Dev Biol Stand; 1979; 44():153-63. PubMed ID: 94568
[TBL] [Abstract][Full Text] [Related]
20. [Bound IgG, IgM, IgA and complement in the epidermis of the growth zone of skin tumors].
Beletskaia LV; Berenbeĭn BA; Silagadze DG; Ezhov NIa
Vestn Dermatol Venerol; 1981 Jan; (1):13-6. PubMed ID: 7210863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
